Filing Flows › Exelixis (EXEL) › Recalls, complaints & regulation
Exelixis (EXEL): clinical trials
Exelixis (EXEL) beyond its filings: 22 active clinical trials.
Exelixis' latest quarter
Exelixis, Q3 2026: revenue $659M (+10% year over year), operating margin 40.8%, net earnings $218M, operating cash flow $280M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Exelixis have?
22 active studies on ClinicalTrials.gov, 10 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.